# Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | H. Wilke,Kei Muro,Eric Van Cutsem,Sang-Cheul Oh,G. Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae‐You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer A. Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D. Schwartz,Atsushi Ohtsu |
| Citations | 2,486 |
| DOI | 10.1016/s1470-2045(14)70420-6 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2111237964 |
| PMID | 25240821 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Jonathan D. Schwartz](https://scholariq.org/researchers/jonathan-d-schwartz/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Paper topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Helicobacter pylori-related gastroenterology studies](https://scholariq.org/topics/helicobacter-pylori-related-gastroenterology-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.